NCT07211802View on ClinicalTrials.gov

CKM For Safe Use of SGLT2i in Type 1 Diabetes

PHASE3Not yet recruitingINTERVENTIONAL
Enrollment

52

Participants

Timeline

Start Date

July 1, 2026

Primary Completion Date

July 31, 2030

Study Completion Date

December 31, 2030

Conditions
Type 1 Diabetes (T1D)
Interventions
DRUG

Sotagliflozin Low Dose

200 mg Sotagliflozin, once daily for 6 weeks

DRUG

Sotagliflozin High Dose

400 mg Sotagliflozin, once daily for 6 weeks

DEVICE

Dual Continuous Glucose and Ketone Monitor

Abbott Libre X dual continuous glucose and ketone monitor (DGK) device.

Trial Locations (1)

92037

UCSD - Altman Clinical & Translational Research Institute, La Jolla

Sponsors
All Listed Sponsors
collaborator

National Institutes of Health (NIH)

NIH

collaborator

Abbott

INDUSTRY

collaborator

Lexicon Pharmaceuticals

INDUSTRY

collaborator

National Institute of Diabetes and Digestive and Kidney Diseases (NIDDK)

NIH

lead

University of California, San Diego

OTHER